ID   Daoy EZHIP KO
AC   CVCL_C8V5
SY   C67-KO Daoy
DR   Wikidata; Q123031155
RX   PubMed=33186520;
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 33738; EZHIP.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Phe (c.725G>T); ClinVar=VCV000376578; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Brain, posterior fossa; UBERON=UBERON_0008788.
DI   NCIt; C129442; Medulloblastoma, SHH-activated, TP53-mutant
DI   ORDO; Orphanet_616; Medulloblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1167 ! Daoy
SX   Male
AG   4Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=33186520; DOI=10.1016/j.ccell.2020.10.009; PMCID=PMC8455074;
RA   Han J.-C., Yu M., Bai Y.-Q., Yu J.-Z., Jin F., Li C., Zeng R.,
RA   Peng J.-H., Li A., Song X.-M., Li H., Wu D.-Q., Li L.;
RT   "Elevated CXorf67 expression in PFA ependymomas suppresses DNA repair
RT   and sensitizes to PARP inhibitors.";
RL   Cancer Cell 38:844-856.e7(2020).
//